Status:

COMPLETED

Use of Endobronchial Valves in Non-Upper Lobe Heterogeneous Emphysema

Lead Sponsor:

Royal Brompton & Harefield NHS Foundation Trust

Conditions:

Heterogeneous Emphysema

Eligibility:

All Genders

18-80 years

Phase:

PHASE3

Brief Summary

Hypothesis: Patients with advanced emphysema with predominance of the disease in areas other than the upper lobes, as determined by high resolution computed tomography (HRCT), could have a positive re...

Eligibility Criteria

Inclusion

  • Age 18-80 years
  • Ex-smoker with smoking cessation confirmed by exhaled carbon monoxide (CO) levels
  • Moderate to severe airflow obstruction FEV1 \<50% Predicted
  • Severe dyspnoea - mMRC ≥2
  • Hyperinflation - total lung capacity (TLC) ≥100% predicted, RV ≥150% predicted
  • SWT ≥75m
  • Optimum COPD treatment for at least 6 weeks
  • No COPD exacerbation for at least 6 weeks
  • Less than 4 admissions for exacerbation in the preceding 12 months

Exclusion

  • Patient unable to provide informed consent
  • Patient without clear targets for airflow re-distribution
  • Total lung CO uptake (TLCO) \<15% predicted and FEV1 \<15% predicted
  • pO2 on air \<6.0kPa
  • pCO2 on air \>8.0kPa
  • Neurological, rheumatological or other cause of exercise limitation
  • Other major medical illness, e.g. lung cancer that will limit participation
  • Production of purulent sputum more often than not (more than 50% of days)
  • Clinically significant bronchiectasis
  • Large bulla - more than 1/3 of hemithorax volume (i.e. where bullectomy would be more suitable) on CT scan
  • Arrhythmia or cardiovascular disease that poses a risk during procedure or exercise
  • Prednisolone dose greater than 15mg a day
  • Significant pulmonary hypertension - RVSP ≥45mmHg
  • Left ventricular failure - left ventricular ejection fraction \<45% or left ventricular fraction shortening \<23%
  • Prior LVRS or lobectomy
  • Lung nodule requiring surgery
  • Subject completed or is participating in a standard pulmonary rehabilitation program within 3 months of enrolment
  • Female of childbearing age with positive pregnancy test
  • Subject participated in a research study of investigational drug or device in prior 30 days
  • Subject taking clopidogrel, warfarin, or other anticoagulants and unable to abstain for 5 days pre-procedure

Key Trial Info

Start Date :

January 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2010

Estimated Enrollment :

32 Patients enrolled

Trial Details

Trial ID

NCT00825578

Start Date

January 1 2009

End Date

December 1 2010

Last Update

February 6 2012

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Royal Brompton Hospital

London, United Kingdom, SW3 6NP